| 1 |
Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before matinib with long-term follow-up.Am J Surg Pathol,2006,30(4):477-489.
|
| 2 |
Joensuu H,Fletcher C,Dimitrijevic S,et al.Management of malignant gastrointestinal stromal tumours.Lancet Oncol,2002,3(11):655.
|
| 3 |
Joensuu H,Roberts PJ,Sarlomo-Rikala M,et al.Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor.N Engl J Med,2001,344(14):1052-1056.
|
| 4 |
Demetri G,von Mehren M,Blanke C,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med,2002,347(7):472-480.
|
| 5 |
van Oosterom A,Judson I,Verweij J,et al.Safety and efficacy of imatinib(STI571)in metastatic gastrointestinal stromal tumours:a phase I study.Lancet,2001,358(9291):1421-1423.
|
| 6 |
Verweij J,van Oosterom A,Blay J,et al.Imatinib mesylate(STI-571 Glivec,Gleevec)is an active agent for gastrointestinal stromal tumours,but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.Eur J Cancer,2003,39(14):2006-2011.
|
| 7 |
Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet,2004,364(9440):1127-1134.
|
| 8 |
Benjamin RS,Rankin C,Fletcher C,et al.Phase III dose-randomized study of imatinib mesylate(STI 571)for GIST:Intergroup S0033 early results[abstract].Proc Am Soc Clin Oncol,2003;22:814.
|
| 9 |
Fletcher C,Berman J,Corless C,et al.Diagnosis of gastrointestinal stromal tumors:a consensus approach.Hum Pathol,2002,33(5):459-465.
|
| 10 |
Corless CL,Fletcher JA,Heinrich MC.Biology of gastrointestinal stromal tumors.J Clin Oncol,2004,22(18):3813-3825.
|
| 11 |
Heinrich MC,Corless CL,Duensing A,et al.PDGFRA activating mutations in gastrointestinal stromal tumors.Science,2003,299(5607):708-710.
|
| 12 |
Tuveson DA,Willis NA,Jacks T,et al.STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein:biological and clinical implications.Oncogene,2001,20(36):5054-5058.
|
| 13 |
Choi H,Charnsangavej C,Faria SC,et al.Correlation of computed tomography(CT)and positron emission tomography(PET)in patients with metastatic GIST treated at a single institution with imatinib mesylate:proposal of new CT response criteria.J Clin Oncol,2007,25(13):1753-1759.
|
| 14 |
Benjamin RS,Choi H,Macapinlac HA,et al.We should desist using RECIST,at least in GIST.J Clin Oncol,2007,25(13):1760-1764.
|
| 15 |
Choi H,Charnsangavej C,Faria SC,et al.CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment:a quantitative analysis correlated with FDG PET findings.AJR Am J Roentgenol,2004,183(6):1619-1628.
|
| 16 |
Le Cesne A,Van Glabbeke M,Verweij J,et al.Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate(IM)included in the intergroup EORTC/ISG/AGITG trial?J Clin Oncol,2006,24(suppl 1):522.
|
| 17 |
Fletcher C,Berman J,Corless C,et al.Diagnosis of gastrointestinal stromal tumors:a consensus approach.Int J Surg Pathol,2002,10(2):81-89.
|
| 18 |
Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol, 2006, 24(29):4764-4774.
|
| 19 |
Blanke CD,Demetri GD,von Mehren M,et al.Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.J Clin Oncol,2008,26(4):620-625.
|
| 20 |
Heinrich MC,Corless CL,Demetri GD,et al.Kinase mutations and imatinib mesylate response in patients with metastatic gastrointestinal stromal tumor.J Clin Oncol,2003,21(23):4342-4349.
|
| 21 |
Debiec-Rychter M,Sciot R,Le Cesne A,et al.KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.Eur J Cancer,2006,42(8):1093-1103.
|
| 22 |
Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.Cancer Res,2004,64(17):5913-5919.
|
| 23 |
Antonescu CR,Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res,2005,11(11):4182-4190.
|
| 24 |
Prenen H,Cools J,Mentens N,et al.Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.Clin Cancer Res,2006,12(8):2622-2627.
|
| 25 |
Demetri GD,van Oosterom AT,Garrett CR,et al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib:a randomised controlled trial.Lancet,2006,368(9544):1329-1338.
|
| 26 |
Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.J Clin Oncol,2005,23(23):5357-5364.
|
| 27 |
Raut CP,Posner M,Desai J,et al.Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted sysemic therapy using kinase inhibitors.J Clin Oncol,2006,24(15):2325-2331.
|
| 28 |
Andtbacka RH,Ng CS,Scaife CL,et al.Surgical resection of gasrointestinal stromal tumors after treatment with imatinib.Ann Surg Oncol,2007,14(1):14-24.
|
| 29 |
Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.Ann Surg,2007,245(3):341-346.
|
| 30 |
DeMatteo RP,Maki RG,Singer S,et al.Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor(GIST).Ann Surg,2007,245(3):347-352.
|